Loading stock data…
DRUG
$86.96-0.99 (-1.13%)
Market ClosedLast close May 1
Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Bright Minds Biosciences Inc. in the Healthcare sector is trading at $86.96. The stock is currently 30% below its 52-week high of $123.75, remaining 31.1% above its 200-day moving average. Technical signals show neutral RSI of 54 and bearish MACD signal, explaining why DRUG maintains its current momentum and trend strength. The Whystock Score of 60/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Neutral momentum (RSI 54) — price action in range
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$86.96
Potential Upside
5%
Whystock Fair Value$91.31
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus3 analysts
Mean target$162.72+87.1%
Range$145.99 – $194.63
Fundamentals
Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio includes 5-HT2 Receptors, which are serotonin agonists for epile...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$882.75M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
-0.11
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-22.23%
Volume
Today's trading volume
371,819
Recent News
What Is the Probability of Success for Bright Minds Biosciences Inc (DRUG)’s Lead Drug Candidate?
Bright Minds Biosciences Inc (NASDAQ:DRUG) is among the best psychedelic stocks to buy in 2026. The company has multiple psychedelic drug candidates, including potential medicines for epilepsy. Its flagship product candidate is BMB-101, which is being developed as a treatment for absence epilepsy. On March 5, H.C. Wainwright weighed on Bright Minds Biosciences Inc. (NASDAQ:DRUG) […]
Psychedelic: Helus Pharma reports HLP004 Phase 2 signal detection study results
In this week’s “Psychedelic,” The Fly’s recurring series focused on psychedelic stock news, The Fly looks back on study results, FDA alignment and a DSMB recommendation. Claim 70% Off TipRanks PremiumUnlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential HELUS PHARMA REPORTS PHASE 2 HLP004 RESULTS: Helus Pharma (HELP) announced Thursday topline results from a Phase
Baird Lowers Bright Minds Biosciences Inc. (DRUG) Price Target to $126, Maintains Outperform Rating Ahead of Upcoming Trials
Bright Minds Biosciences Inc. (NASDAQ:DRUG) is among the 7 Most Promising Psychedelic Stocks According to Hedge Funds. Bright Minds Biosciences Inc. (NASDAQ:DRUG) is among the most promising stocks. TheFly reported on February 13 that Baird lowered its price target for DRUG to $126 from $142 and maintained an Outperform rating on the shares. The update […]
Recent Price Trend in Bright Minds Biosciences Inc. (DRUG) is Your Friend, Here's Why
Bright Minds Biosciences Inc. (DRUG) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Wall Street Analysts Think Bright Minds Biosciences Inc. (DRUG) Could Surge 36.27%: Read This Before Placing a Bet
The average of price targets set by Wall Street analysts indicates a potential upside of 36.3% in Bright Minds Biosciences Inc. (DRUG). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.